Clinuvel Pharmaceuticals Limited Price Chart
Clinuvel Pharmaceuticals Limited CUV.XA Financial and Trading Overview
| Clinuvel Pharmaceuticals Limited stock price | 15.43 AUD |
| Previous Close | 18.81 AUD |
| Open | 18.73 AUD |
| Bid | 18.45 AUD x N/A |
| Ask | 18.6 AUD x N/A |
| Day's Range | 18.51 - 18.99 AUD |
| 52 Week Range | 13.51 - 28.6 AUD |
| Volume | 4.26K AUD |
| Avg. Volume | 6.5K AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.877011 |
| PE Ratio (TTM) | 39.43298 |
| EPS (TTM) | 0.47 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CUV.XA Valuation Measures
| Enterprise Value | 744.88M AUD |
| Trailing P/E | 39.43298 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 6.5791626 |
| Enterprise Value/Revenue | 10.507 |
| Enterprise Value/EBITDA | 18.196 |
Trading Information
Clinuvel Pharmaceuticals Limited Stock Price History
| Beta (5Y Monthly) | 0.877011 |
| 52-Week Change | 31.26% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 28.6 AUD |
| 52 Week Low | 13.51 AUD |
| 50-Day Moving Average | 19.43 AUD |
| 200-Day Moving Average | 20.46 AUD |
CUV.XA Share Statistics
| Avg. Volume (3 month) | 6.5K AUD |
| Avg. Daily Volume (10-Days) | 2.48K AUD |
| Shares Outstanding | N/A |
| Float | 37.13M |
| Short Ratio | N/A |
| % Held by Insiders | 20.55% |
| % Held by Institutions | 8.87% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.04 |
| Trailing Annual Dividend Yield | 0.21% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 37.23% |
| Operating Margin (ttm) | 57.16% |
| Gross Margin | 89.75% |
| EBITDA Margin | 57.74% |
Management Effectiveness
| Return on Assets (ttm) | 18.35% |
| Return on Equity (ttm) | 21.42% |
Income Statement
| Revenue (ttm) | 70.89M AUD |
| Revenue Per Share (ttm) | 1.44 AUD |
| Quarterly Revenue Growth (yoy) | 19.19% |
| Gross Profit (ttm) | 56.92M AUD |
| EBITDA | 40.94M AUD |
| Net Income Avi to Common (ttm) | 26.4M AUD |
| Diluted EPS (ttm) | 0.47 |
| Quarterly Earnings Growth (yoy) | 94.00% |
Balance Sheet
| Total Cash (mrq) | 140.7M AUD |
| Total Cash Per Share (mrq) | 2.85 AUD |
| Total Debt (mrq) | 1.14M AUD |
| Total Debt/Equity (mrq) | 0.82 AUD |
| Current Ratio (mrq) | 8.798 |
| Book Value Per Share (mrq) | 2.817 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 43.57M AUD |
| Levered Free Cash Flow (ttm) | 38.71M AUD |
Profile of Clinuvel Pharmaceuticals Limited
| Country | Australia |
| State | VIC |
| City | Melbourne |
| Address | 535 Bourke Street |
| ZIP | 3000 |
| Phone | 61 3 9660 4900 |
| Website | https://www.clinuvel.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Q&A For Clinuvel Pharmaceuticals Limited Stock
What is a current CUV.XA stock price?
Clinuvel Pharmaceuticals Limited CUV.XA stock price today per share is 15.43 AUD.
How to purchase Clinuvel Pharmaceuticals Limited stock?
You can buy CUV.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clinuvel Pharmaceuticals Limited?
The stock symbol or ticker of Clinuvel Pharmaceuticals Limited is CUV.XA.
How many shares does Clinuvel Pharmaceuticals Limited have in circulation?
The max supply of Clinuvel Pharmaceuticals Limited shares is 0.
What is Clinuvel Pharmaceuticals Limited Price to Earnings Ratio (PE Ratio)?
Clinuvel Pharmaceuticals Limited PE Ratio is 32.82064000 now.
What was Clinuvel Pharmaceuticals Limited earnings per share over the trailing 12 months (TTM)?
Clinuvel Pharmaceuticals Limited EPS is 0.47 AUD over the trailing 12 months.